Table 2.
Association between VEGF genotypes and overall survival
| Genotypes | Case No. | Deaths No. (%)* | MST (95% CI, month) | Crude HR (95% CI) | P† | Adjusted HR (95% CI) | P‡ |
|---|---|---|---|---|---|---|---|
| VEGF -460T > C (rs833061) | |||||||
| TT | 33 | 28 (84.9) | 16.0 (11.0-25.0) | 1.00 | 1.00 | ||
| CT | 67 | 47 (70.2) | 21.0 (17.0-32.0) | 0.60 (0.37-0.95) | 0.031 | 0.56 (0.34-0.90) | 0.018 |
| CC | 24 | 17 (70.8) | 27.0 (10.0-36.0) | 0.75 (0.41-1.37) | 0.347 | 0.67 (0.36-1.26) | 0.212 |
| CT+CC | 91 | 64 (70.3) | 21.0 (17.0-31.0) | 0.63 (0.40-0.99) | 0.043 | 0.58 (0.37-0.92) | 0.022 |
| VEGF -634G > C (rs2010963) | |||||||
| GG | 57 | 40 (70.2) | 23.0 (16.0-36.0) | 1.00 | 1.00 | ||
| CG | 41 | 34 (82.9) | 17.0 (13.0-25.0) | 1.20 (0.76-1.90) | 0.440 | 1.17 (0.74-1.88) | 0.502 |
| CC | 26 | 18 (69.2) | 12.0 (9.0-29.0) | 1.25 (0.71-2.18) | 0.436 | 1.28 (0.72-2.28) | 0.399 |
| CG+CC | 67 | 52 (76.1) | 17.0 (12.0-24.0) | 1.22 (0.80-1.84) | 0.356 | 1.21 (0.79-1.84) | 0.379 |
| VEGF +936C > T (rs3025039) | |||||||
| CC | 92 | 68 (73.9) | 21.0 (16.0-29.0) | 1.00 | 1.00 | ||
| CT | 30 | 22 (73.3) | 17.0 (11.0-29.0) | 1.08 (0.67-1.75) | 0.742 | 1.00 (0.60-1.66) | 0.992 |
| TT | 2 | 2 (100) | 14.5 (9.0-20.0) | 2.14 (0.52-8.80) | 0.291 | 1.95 (0.46-8.29) | 0.367 |
| CT+TT | 32 | 24 (75.0) | 17.0 (11.0-28.0) | 1.13 (0.71-1.80) | 0.606 | 1.05 (0.65-1.71) | 0.839 |
Abbreviation: MST, median survival time.
* Percentage of deaths in each stratum
† P values were calculated using the log-rank test in the univariate analysis.
‡ P values were obtained from the Cox hazards model with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of chemotherapy and radiotherapy dose.